Understanding HPLC purity reports — a researcher's guide

Every Nexus Laboratory Certificate of Analysis reports an HPLC area-percent purity value. That single number is the easiest line on the COA to read — and one of the easier ones to misread. This article walks through what HPLC purity actually measures, what the value does and does not tell you about the compound in the vial, and the common artifacts that should change how you weight the result in research planning.

What HPLC area-percent measures

Reverse-phase high-performance liquid chromatography (RP-HPLC) separates the components of a sample by their interactions with a stationary phase (typically a C18-modified silica column) under a controlled mobile-phase gradient. A UV detector at a fixed wavelength (commonly 220 nm for peptides) records the absorbance signal as the gradient elutes each component. The result is a chromatogram — absorbance versus time — with peaks corresponding to the eluted compounds.

Area-percent purity is the integrated peak area of the main compound divided by the total integrated area of all UV-active peaks in the chromatogram, expressed as a percentage. A 99.5% area-percent value means 99.5% of the integrated UV signal was the main peak, and 0.5% was the sum of everything else.

What it does NOT measure

The value is relative chromatographic signal — not absolute compound content. Several things HPLC area-percent does not directly capture:

• Water content. Lyophilized peptides retain residual moisture (typically 2-5%). HPLC area-percent does not measure it; net peptide content per vial is determined separately, typically by Karl Fischer titration or amino-acid analysis.
• Non-UV-active impurities. Salts (acetate, trifluoroacetate counterions), residual solvents, and inorganic contaminants generally absorb weakly at 220 nm and contribute little to the chromatogram. They are not in the area-percent calculation.
• Compound identity. HPLC purity says the main peak is 99% of UV signal — it does not say the main peak is the right molecule. Mass spectrometry confirms identity; area-percent does not.
• Co-eluting impurities. Two compounds with similar retention times can co-elute and read as a single peak. The area-percent value over-counts when this happens. Method validation includes peak-purity assessment (typically by photodiode-array spectral similarity) but this is not always reported.

Common artifacts and how to interpret them

Shoulder peaks

A small peak immediately before or after the main peak typically represents a closely-related synthesis impurity — a single-residue deletion, a deamidation product, or an oxidation variant. The area-percent value subtracts the shoulder; the COA may report both the main peak and a labeled minor peak. Shoulders below 0.5% are common in 99% peptides.

Tailing or fronting peaks

Peak shape distortion can come from column overload (too much sample injected), pH-dependent ionization effects, or column degradation. It typically does not change the integrated area meaningfully but may affect peak-purity assessment if multiple species are eluting under the same envelope.

Wavelength-specific blindness

A 220 nm UV detector responds well to the peptide backbone (amide bond) but variably to side chains. Compounds containing only aliphatic side chains can be undercounted; compounds containing aromatic residues (tyrosine, tryptophan, phenylalanine) have strong absorbance. For peptides where this matters, an additional measurement at 280 nm or PDA-based spectral analysis is useful.

Why ≥98% matters for research reproducibility

Research applications that depend on quantitative dose-response work — receptor-binding affinity measurements, in-vitro EC50/IC50 determinations, structure-activity relationship studies — require accurate compound content. A 95%-pure compound used at a calculated 1 μM concentration is effectively a 0.95 μM concentration in the experiment; the impurity mix contributes additional noise. The Nexus release threshold (≥98% HPLC area-percent, target ≥99% on common compounds) is calibrated to keep impurity-noise below the typical experimental signal threshold.

For research applications where the compound is used qualitatively — receptor-pharmacology screening, exploratory binding studies — the practical purity floor is lower. But the COA documents the actual value, so the researcher can scale their interpretation. Hiding the value below an arbitrary "≥99%" marketing claim would prevent that scaling.

What to ask of an HPLC purity claim

When evaluating a research peptide supplier, four questions about an HPLC purity claim are worth asking. The Nexus Certificate of Analysis answers all four:

• What method was used? (Column type, mobile phase composition, gradient, detection wavelength, sample concentration, injection volume.)
• What was the retention time of the main peak? (Documented per batch — useful for cross-batch comparison.)
• Who ran the analysis? (In-house QC or an independent third-party laboratory. Nexus uses independent third-party labs for every batch.)
• What is the date of testing? (Compounds degrade over time; a COA dated three years ago is informative about the historical batch but not the current vial.)

The HPLC area-percent value is a useful single-number summary of compound purity, but it is most useful when paired with the method, the mass spectrometry identity confirmation, the testing lab, and the date. The full Certificate of Analysis answers all four — that is the difference between a research-grade compound with documented chemistry and a marketed purity claim.